(Q42911213)

English

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline

scientific article published on October 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline (English)

1 reference

Europe PubMed Central

11 November 2017

chronic hepatitis B

1 reference

based on heuristic

inferred from title

peginterferon alfa-2b

1 reference

based on heuristic

inferred from title

chronic hepatitis

1 reference

based on heuristic

inferred from title

4

1 reference

Europe PubMed Central

11 November 2017

Vincent Rijckborst

2

object named as

Vincent Rijckborst

1 reference

Europe PubMed Central

11 November 2017

author name string

Milan J Sonneveld

1

1 reference

Europe PubMed Central

11 November 2017

Charles A B Boucher

3

1 reference

Europe PubMed Central

11 November 2017

Harry L A Janssen

5

1 reference

Europe PubMed Central

11 November 2017

language of work or name

0 references

publication date

1 October 2010

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

52

1 reference

Europe PubMed Central

11 November 2017

4

1 reference

Europe PubMed Central

11 November 2017

1251-1257

1 reference

Europe PubMed Central

11 November 2017

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

21 January 2018

Hepatitis B Virus Infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Endpoints of therapy in chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

National Institutes of Health Consensus Development Conference Statement: management of hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B: reflections on the current approach to antiviral therapy.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Pegylated interferons for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantitation of hepatitis B surface antigen by an automated chemiluminescent microparticle immunoassay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Methods for categorizing a prognostic variable in a multivariable setting

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of quantitative hepatitis B serology in the natural history and management of chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Predicting cirrhosis risk based on the level of circulating hepatitis B viral load

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level

1 reference

https://api.crossref.org/works/10.1002%2FHEP.23844

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP.23844

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42911213&oldid=1973508857"